ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,179.68
-0.55%
Dow Jones
39,164.06
0.09%
Gold vs US Dollar
2,327.44
1.27%
Brent Oil
85.415
1.12%
Bitcoin
61,610.73
1.31%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Cyclacel Pharmaceuticals Inc (CYCCP) Share Price

CYCCP Cyclacel Pharmaceuticals Inc

10.70
3.20 (42.67%)
After Hours
Last Updated: 21:48:30
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Cyclacel Pharmaceuticals Inc NASDAQ:CYCCP NASDAQ Preference Share  6% Convertible PFD
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   3.20 42.67 10.70 10.70 27.50 11.09 7.45 7.45 29,588 20:48:30   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 420k -22.76M -15.5516 -0.11 2.49M
 Type  Size  Price  Time  Units 
 13 100 10.70 20:00:00 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore CYCCP News
26/06/202414:15GLOBECyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
04/06/202413:00GLOBECyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
03/06/202413:00GLOBECyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
17/05/202414:56EDGAR2Form D - Notice of Exempt Offering of Securities
14/05/202422:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/05/202421:05EDGAR2Form 8-K - Current report
14/05/202421:05GLOBECyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
Period
Draw mode
Data Downloads for CYCCP

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Cyclacel Pharmaceuticals Inc Articles